We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01597947
Recruitment Status : Completed
First Posted : May 15, 2012
Last Update Posted : January 21, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
This is a double-blind, randomized, placebo-controlled, single ascending dose study to assess the safety, tolerability, and PK of ACHN-975 in normal healthy volunteers. This study will take place in the US at one clinical site.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: ACHN-975 Drug: placebo Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) ACHN-975 in Normal Healthy Volunteers
Study Start Date : May 2012
Study Completion Date : December 2012
Arms and Interventions

Arm Intervention/treatment
Experimental: Arm A Drug: ACHN-975
Intravenous single dose
Placebo Comparator: Arm B Drug: placebo
Intravenous single dose

Outcome Measures

Primary Outcome Measures :
  1. Frequency of AEs [ Time Frame: 7 days ]
  2. Severity of AEs [ Time Frame: 7 days ]

Secondary Outcome Measures :
  1. Plasma concentrations of ACHN-975 [ Time Frame: 2 days ]
  2. Urine concentrations of ACHN-975 [ Time Frame: 2 days ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Key Inclusion Criteria:

  • Body weight between 40 and 100 kilograms (between ~88 pounds and ~220 pounds)
  • Use of contraception
  • Stable health
  • Negative tests for alcohol, tobacco, and drugs of abuse

Key Exclusion Criteria:

  • History of clinically significant disease
  • Pregnancy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01597947

United States, North Carolina
Investigational Site
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Achaogen, Inc.
Defense Medical Research and Development Program
Study Director: Medical Director Achaogen, Inc.
More Information

Responsible Party: Achaogen, Inc.
ClinicalTrials.gov Identifier: NCT01597947     History of Changes
Other Study ID Numbers: ACHN-975-001
First Posted: May 15, 2012    Key Record Dates
Last Update Posted: January 21, 2013
Last Verified: January 2013